Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Therapeutic biomarkers of EGFR-TKI].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 Nov 2012

Seike Masahiro, Gemma Akihiko

Abstract excerpt

Non-small cell lung cancer(NSCLC)patients with activating mutations of the epidermal growth factor receptor(EGFR)gene have shown a dramatic response to EGFR tyrosine kinase inhibitors(EGFR-TKI)such as gefitinib and erlotinib. EGFR activating mutations including exon 19 deletion and exon 21 L858R are recognized as markers ofthe sensitivity to EGFR-TKI therapy in NSCLC. However, the emergence of acquired resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to FAS gene

Share to HGF gene

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 23152012

Genes

EGFR
FAS
HGF
MET
PTEN

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Therapeutic biomarkers of EGFR-TKI].PMID 23152012Read ↗

Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.Semantic proximity Read ↗

MET: a new promising biomarker in non-small-cell lung carcinoma.Semantic proximity Read ↗

Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer.Semantic proximity Read ↗

[The mechanisms of resistance to EGFR-TKIs and challenges to overcome resistance in EGFR mutant non-small cell lung cancer].Semantic proximity Read ↗

Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

Recent Developments and Challenges in Molecular-Targeted Therapy of Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors.Semantic proximity Read ↗

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.Semantic proximity Read ↗

Mechanisms of resistance to EGFR tyrosine kinase inhibitorsSemantic proximity Read ↗

Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.Semantic proximity Read ↗

[Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer].Semantic proximity Read ↗

Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.